Abstract
Background Huntington’s disease (HD) and Parkinson’s disease (PD) are neurodegenerative diseases resulting in motor impairments of gait initiation (GI). However, the neurophysiological underpinnings of GI in HD and PD are not well understood. The aims of this study were to 1) evaluate the feasibility of a wireless EEG system to identify EEG-derived movement-related potentials (MRPs) in individuals with HD and PD during GI, and to 2) determine the tolerance of a high repetition GI protocol.
New Method 3 participants with HD and 3 participants with PD performed 3 blocks of 15 trials of GI. EEG-derived MRPs of readiness potential (RPs) and contingent negative variation (CNV) were identified during GI, using a wireless EEG system synced with kinetic measures of GI. Tolerance of the protocol was determined from changes in COP across GI blocks.
Results There were no differences between HD and PD for CNV and RP amplitudes and latencies, although they were within acceptable ranges of MRP values in HD and PD. There were no differences of COP values between GI blocks.
Comparison with old method A wireless EEG system elicits naturalistic GI biomechanical responses as opposed to previous methods employing tethered systems. In contrast to single-trial EEG studies, this study implemented a larger number of GI trials, which produces greater MRP resolution.
Conclusions This study validated the use of a wireless EEG headset in determining MRP values during GI in HD and PD. Participants within these populations were able to tolerate a high repetition GI protocol. Future work will explore MRPs in larger cross-sectional studies for the development of clinical outcome measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research protocol was approved by the Institutional Review Boards at Teachers College Columbia University and through the Huntingtons Disease Society of America Center of Excellence at Columbia University and the PD Registry at Teachers College.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
lq2165{at}tc.columbia.edu
Data Availability
All data produced in the present study are available upon reasonable request to the author.